Heart failure & cardiomyopathies
Long-Term Impact of Angiotensin Receptor-Neprilysin Inhibitor Based on Short-Term Treatment Response in Heart Failure
Authors' conclusion
Regardless of significant treatment response measured by either LVEF or LV reverse remodelling after 1 year of treatment, the extended utilization of ARNI demonstrated a more favourable prognosis than that of ACEIs/ARBs in patients with HFrEF.
Study context
- Population
- Patients with HF with reduced ejection fraction (HFrEF) treated with angiotensin receptor-neprilysin inhibitor (ARNI) or ACEi/ARB, reclassified after 1 year of treatment by heart failure (HF) with improved EF vs persistent HFrEF and by left ventricular (LV) reverse remodelling133 (19.8%) composite events
- Participants
- 671 patients
- Exposure
- ARNI vs ACEi/ARB
- Outcome
- Composite of:
- All-cause mortality
- HF hospitalization
- Follow-up
- Median 44 [IQR 34-51] months
Main finding
As reported in the abstract
Composite event rate, by treatment-response subgroup
- ARNI vs angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs): P = 0.020
- ARNI vs ACEIs/ARBs: P < 0.001
- ARNI vs ACEIs/ARBs: P = 0.001
- ARNI vs ACEIs/ARBs: P < 0.001
Observational data: associations, not effects.
Original publication
Long-Term Impact of Angiotensin Receptor-Neprilysin Inhibitor Based on Short-Term Treatment Response in Heart Failure. ESC Heart Fail. Published 13 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →